Diabetology & Metabolic Syndrome is calling for submissions to our Collection on Diabetes and metabolic syndrome associated with infectious diseases. Around the prevalence of infectious disease such as viral hepatitis, tuberculosis, AIDS, COVID-19, and so on, with metabolic diseases, prognostic factors, manifestations of metabolic abnormalities, comorbidity characteristics, potential mechanisms of comorbidity mutual influence, key technologies for standardized diagnosis, treatment, and comprehensive management of comorbidities.
• Viral hepatitis accompanied by metabolic disorders: the prevalence of viral hepatitis with metabolic diseases, prognostic factors, manifestations of metabolic abnormalities, comorbidity characteristics, potential mechanisms of comorbidity mutual influence, key technologies for standardized diagnosis, treatment, and comprehensive management of comorbidities. Continuous Subcutaneous Insulin Infusion with insulin pump combined with Continuous Glucose Monitoring System treatment of liver disease with diabetes, the impact of blood glucose fluctuations and hypoglycemic events on the prognosis of liver failure patients, the impact of non biological artificial liver on glucose metabolism, the relationship between insulin resistance and inflammation and fibrosis, and the impact of hepatitis B virus infection on pancreatic islets β cell function.
• Metabolic diseases associated with AIDS: the prevalence of metabolic diseases in AIDS patients, short-term and long-term dynamic effects of antiviral treatment on metabolism, characteristics and dynamic changes of metabolism in AIDS patients with fatty liver, AIDS patients with abnormal bone metabolism and osteoporosis.
• Tuberculosis complicated with diabetes: comorbidity characteristics, cavity formation, sputum bacteria positive, focus distribution, tuberculosis and HIV double sensitivity, drug resistance characteristics, prognosis and influencing factors.
• COVID-19 and its concomitant metabolic and cardio cerebrovascular diseases: distribution characteristics of comorbidities and their relationship with disease progress and prognosis, dynamic impact of comorbidities on immunity, dynamic characteristics of cellular immunity, immune breakthrough and its impact on disease progress and prognosis, the relationship between the dynamic changes of lymphocyte subsets and the disease progress and prognosis in patients with and without diabetes, the analysis of early warning factors for severe disease, the dynamic characteristics of specific antibodies in different disease severity groups and related factors, the follow-up of COVID-19 in the rehabilitation period and the key technology research of community rehabilitation.
